SUMOylation modulates the function of Aurora-B kinase

Citation for published version:

Digital Object Identifier (DOI):
10.1242/jcs.065565

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Cell Science

Publisher Rights Statement:
RoMEO green

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
SUMOylation modulates the function of Aurora-B kinase

Gonzalo Fernández-Miranda1, Ignacio Pérez de Castro1, Mar Carmen2, Cristina Aguirre-Portolés1, Sandrine Ruchaud2, Xavier Fant2, Guillermo Montoya3, William C. Earnshaw2 and Marcos Malumbres1, *  
1Cell Division and Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, E-28029, Spain  
2Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, EH9 3JR, UK  
3Macromolecular Crystallography Group, CNIO, Madrid, Spain  
*Author for correspondence (malumbres@cnio.es)

Summary

Aurora kinases are central regulators of mitotic-spindle assembly, chromosome segregation and cytokinesis. Aurora B is a member of the chromosomal passenger complex (CPC) with crucial functions in regulation of the attachment of kinetochores to microtubules and in cytokinesis. We report here that Aurora B contains a conserved SUMO modification motif within its kinase domain. Aurora B can bind SUMO peptides in vitro when bound to the IN-box domain of its CPC partner INCENP. Mutation of Lys207 to arginine (Aurora B K207R) impairs the formation of conjugates of Aurora B and SUMO in vivo. Expression of the SUMO-null form of Aurora B results in abnormal chromosome segregation and cytokinesis failure and it is not able to rescue mitotic defects in Aurora-B-knockout cells. These defects are accompanied by increased levels of the CPC on chromosome arms and defective centromeric function, as detected by decreased phosphorylation of the Aurora-B substrate CENP-A. The Aurora-B K207R mutant does not display reduced kinase activity, suggesting that functional defects are probably a consequence of the altered localization, rather than decreased intrinsic kinase activity. These data suggest that SUMOylation of Aurora B modulates its function, possibly by mediating the extraction of CPC complexes from chromosome arms during prometaphase.

Key words: Aurora kinases, Cell cycle, Chromosome segregation, Cancer target, SUMO modifications

Introduction

Aurora B (serine/threonine-protein kinase 12) is the enzymatic core of a multiprotein complex, the chromosomal passenger complex (CPC), which comprises other three non-enzymatic subunits, INCENP, Survivin and Borealin (Carmena and Earnshaw, 2003; Ruchaud et al., 2007). The CPC is an important upstream regulator of centromere-kinetochore function, and is responsible for the recruitment to the kinetochore and centromere of a number of proteins, including inner centromere-kinetochore proteins (Sgo1, Sgo2, MCAK), regulators of the microtubule-kinetochore interaction (such as Hecl and Plk1, among others) and proteins involved in the spindle-assembly checkpoint (SAC; such as Mad2, BubR1 and Mps1) (Kelly and Funabiki, 2009; Ruchaud et al., 2007). Some kinetochore components, including Hecl, Dam1, MCAK and CENP-A, are Aurora-B substrates, suggesting a crucial role for the CPC in the destabilization of aberrant microtubule-to-kinetochore attachments and in the SAC-dependent delay of mitotic progression until these defects are corrected. Recent data suggests that substrate phosphorylation depends on the distance of the substrate from Aurora B at the inner centromere, and artificial recruitment of the CPC to the kinetochore prevents the stabilization of improper attachments and activates the SAC to delay the metaphase-to-anaphase transition (Kelly and Funabiki, 2009; Liu et al., 2009). During cytokinesis, Aurora B is localized to the midbody where its local inactivation is crucial for completion of abscission (Guse et al., 2005; Steigemann et al., 2009).

Activity of Aurora B is regulated through several mechanisms, including controlled interactions with INCENP, Survivin and Borealin. Knockdown of any member of the complex delocalizes the others, disrupts mitotic progression and might destabilize one or more subunits (Jeyaprakash et al., 2007; Ruchaud et al., 2007). In addition, several post-translational modifications are known to be required for proper activity and control of the dynamic behavior of the CPC. Activation of Aurora B is triggered by autophosphorylation of the T-loop residue after association with its substrate, INCENP. Full activation involves a positive-feedback loop after Aurora-B phosphorylation of INCENP in the conserved IN-box region, possibly as a result of structural rearrangements (Bishop and Schumacher, 2002; Honda et al., 2003).

Aurora B phosphorylates a number of proteins, including inner centromere-kinetochore proteins (Sgo1, Sgo2, MCAK), regulators of the microtubule-kinetochore interaction (such as Hecl and Plk1, among others) and proteins involved in the spindle-assembly checkpoint (SAC; such as Mad2, BubR1 and Mps1) (Kelly and Funabiki, 2009; Ruchaud et al., 2007). Some kinetochore components, including Hecl, Dam1, MCAK and CENP-A, are Aurora-B substrates, suggesting a crucial role for the CPC in the destabilization of aberrant microtubule-to-kinetochore attachments and in the SAC-dependent delay of mitotic progression until these defects are corrected. Recent data suggests that substrate phosphorylation depends on the distance of the substrate from Aurora B at the inner centromere, and artificial recruitment of the CPC to the kinetochore prevents the stabilization of improper attachments and activates the SAC to delay the metaphase-to-anaphase transition (Kelly and Funabiki, 2009; Liu et al., 2009). During cytokinesis, Aurora B is localized to the midbody where its local inactivation is crucial for completion of abscission (Guse et al., 2005; Steigemann et al., 2009).

Activity of Aurora B is regulated through several mechanisms, including controlled interactions with INCENP, Survivin and Borealin. Knockdown of any member of the complex delocalizes the others, disrupts mitotic progression and might destabilize one or more subunits (Jeyaprakash et al., 2007; Ruchaud et al., 2007). In addition, several post-translational modifications are known to be required for proper activity and control of the dynamic behavior of the CPC. Activation of Aurora B is triggered by autophosphorylation of the T-loop residue after association with its substrate, INCENP. Full activation involves a positive-feedback loop after Aurora-B phosphorylation of INCENP in the conserved IN-box region, possibly as a result of structural rearrangements (Bishop and Schumacher, 2002; Honda et al., 2003).

Aurora kinases are central regulators of mitotic-spindle assembly, chromosome segregation and cytokinesis. Aurora B is a member of the chromosomal passenger complex (CPC) with crucial functions in regulation of the attachment of kinetochores to microtubules and in cytokinesis. We report here that Aurora B contains a conserved SUMO modification motif within its kinase domain. Aurora B can bind SUMO peptides in vitro when bound to the IN-box domain of its CPC partner INCENP. Mutation of Lys207 to arginine (Aurora B K207R) impairs the formation of conjugates of Aurora B and SUMO in vivo. Expression of the SUMO-null form of Aurora B results in abnormal chromosome segregation and cytokinesis failure and it is not able to rescue mitotic defects in Aurora-B-knockout cells. These defects are accompanied by increased levels of the CPC on chromosome arms and defective centromeric function, as detected by decreased phosphorylation of the Aurora-B substrate CENP-A. The Aurora-B K207R mutant does not display reduced kinase activity, suggesting that functional defects are probably a consequence of the altered localization, rather than decreased intrinsic kinase activity. These data suggest that SUMOylation of Aurora B modulates its function, possibly by mediating the extraction of CPC complexes from chromosome arms during prometaphase.
Post-translational modifications by the covalent attachment of small ubiquitin-related modifiers (SUMOs) are important in several cellular processes, including the cell-division cycle (Geiss-Friedlander and Melchior, 2007; Hay, 2005; Ulrich, 2008). In vertebrates, at least three SUMO forms (SUMO1, SUMO2 and SUMO3) are covalently attached to a lysine residue in the target protein in three enzymatic steps analogous to the ubiquitylation cascade. SUMO conjugation requires a SUMO-activating E1 enzyme (SAE1 or SAE2), the SUMO-conjugating E2 enzyme UBC9 and, in some cases, additional E3 SUMO ligases (Hay, 2005). SUMO modification is reversible by the action of SUMO-specific isopeptidases that belong to the family of ubiquitin-like proteases (ULPs), also known as sentrin-specific proteases (SENP) (Hay, 2007). Recent work has revealed the importance of SUMOylation for mitotic progression (Dasso, 2008; Watts, 2007) and has suggested a crucial role of SUMO modifications in kinetochore and centromere function (Dawlaty et al., 2008; Di Bacco et al., 2006; Mukhopadhyay et al., 2010; Zhang et al., 2008), including direct SUMOylation of the CPC component Borealin (Klein et al., 2009).

In this manuscript, we provide evidence for SUMOylation of Aurora B at Lys207. Mutation of this residue results in abnormal mitotic progression and the generation of multinucleated cells. In those mutant cells, Aurora B and INCENP display an abnormal localization at the chromosome arms during prometaphase and metaphase and defective CENP-A phosphorylation, indicating a role for Aurora-B SUMOylation in the proper localization and activity of the CPC during chromosome alignment.

Results

A conserved SUMOylation motif in Aurora-B proteins

Aurora B contains a consensus motif for SUMO modification (Ψ-Lys-x-Glu, in which Ψ is a hydrophobic residue and x, any residue) within the kinase domain (Fig. 1A). This motif is readily identified by using different protein-domain-recognition algorithms (see the Materials and Methods). The SUMO motif is conserved among Aurora-B orthologues from yeast to human, and it is also present in the other mammalian members of the Aurora family, but not in other cell cycle kinases, including Polo-like kinases (Fig. 1A).

To test the possible SUMOylation of this domain, we mutated the lysine (K207) predicted to accept the SUMO peptide into a charge-conservative arginine residue. The Aurora-BK207R mutation is predicted to impair covalent binding of SUMO with little effect on the overall kinase structure. Next, we expressed V5-epitope-tagged versions of wild-type (WT) Aurora-B and Aurora-BK207R mutant forms along with the E2 SUMO ligase UBC9 and HA-tagged versions of the three SUMO isoforms (HA-SUMO1 to HA-SUMO3; ~12 kDa) in HEK293 cells (Fig. 1B). The ectopically expressed proteins were immunoprecipitated using anti-V5 antibodies and detected with antibodies against the HA epitope. The predicted SUMO-Aurora-B conjugates (~50 kDa) were detected after expression of all three SUMO isoforms (Fig. 1B), suggesting that Aurora B can be SUMOylated by the three SUMO peptides in this assay. Importantly, the Aurora-B-SUMO conjugates were not observed in cells expressing the Aurora-BK207R isoform, indicating that K207 is required for covalent modification of Aurora B by SUMO residues.

We next tested SUMOylation of endogenous Aurora B by taking advantage of HeLa cells stably expressing histidine-tagged SUMO2 proteins (~16 kDa). These cells were transfected with V5-Aurora-B-expressing vectors and SUMO2 conjugates were exposed to antibodies against V5 or two different antibodies against Aurora B. SUMO2 conjugates were affinity purified under denaturing conditions with Ni-NTA beads. As depicted in Fig. 2A, all these three antibodies detected a band of ~60 kDa, and possibly additional higher-molecular-weight bands in SUMO2 conjugates. This band was detected in taxol-treated cells and it was barely visible in asynchronously growing cells or in parental cells that do not overexpress SUMO2 (data not shown). An additional band of ~55 kDa that might correspond to the endogenous Aurora-B-(His)SUMO2 conjugates is detected by a monoclonal antibody against Aurora B. In fact, this band was also observed in similar assays in which the V5-Aurora-B vector was not used (data not shown), thus further suggesting modification of the endogenous protein.
We then used a reconstituted in vitro SUMO modification system to further test the molecular requirements for this SUMOylation. Recombinant Aurora B was incubated with SUMO E1-activating enzymes (SAE1/2), the E2-conjugating enzyme UBC9 and SUMO2 in the presence of ATP. A mutant SUMO2 molecule unable to conjugate to substrates was used as a control. As recently suggested (Klein et al., 2009), we did not detect obvious SUMOylation of Aurora B in this assay, whereas p53 was significantly SUMOylated by SUMO2, but not SUMO2 mutant peptides (Fig. 2B). Since Aurora B seems to be SUMOylated in vivo, we then asked whether additional CPC domains were required for this post-translational modification. Indeed, higher-molecular-weight Aurora B conjugates (Fig. 2B, arrows) were observed after incubation of Aurora B with the IN-box segment of INCENP, a domain that directly binds and activates Aurora B (Adams et al., 2000). INCENP-bound Aurora B was conjugated with SUMO2, but not with SUMO2 mutants, indicating the specificity of this signal. All together, these results suggest that Aurora-B K207 can be conjugated to SUMO residues and this modification requires binding of Aurora B to its activator INCENP.

Defective SUMOylation of Aurora B results in abnormal chromosome segregation and reduced cell viability

We transiently transfected HEK293 cells with GFP-tagged vectors for wild-type Aurora B, kinase-dead mutants (Aurora B K111M and Aurora B D205A) and the SUMO-null form (Aurora B K207R) to understand the relevance of SUMOylation of Aurora B in cell-cycle progression. Overexpression of wild-type Aurora B slightly increased the percentage of 4N and >4N cells, which is consistent with a mitotic delay and defects in completion of cytokinesis. These defects were more pronounced upon expression of the kinase-dead form Aurora B K111M (19.1% of >4N) and, at an even higher degree with Aurora B D205A (47.6% of >4N) (Fig. 3A,B). The phenotypic differences observed with the Aurora-B K111M and Aurora-B D205A mutants suggest distinct degrees of inhibition of the kinase activity in these mutants (see below). Interestingly, overexpression of the SUMO-null form (Aurora B K207R) induces polyploidy at the same level as the Aurora-B D205A mutant (44.1% in Aurora-B K207R mutants vs 47.6% in Aurora-B D205A mutants). Microscopy analysis indicated that >4N cells overexpressing the Aurora-B K207R mutant were mostly multinucleated and displayed severe nuclear abnormalities (Fig. 3C), which were similar to those of kinase-dead mutants (not shown). Stable expression of Aurora B D205A and Aurora B K207R in U2OS cells severely reduced the number of colonies, suggesting that mutations in these residues impair Aurora-B function in a way that is incompatible with cell proliferation (Fig. 3D,E).

Altered mitotic progression and cytokinesis in Aurora-B K207R mutants

Deregulation of the function of Aurora B by chemical inhibition, small interfering RNA (siRNA) or overexpression of the kinase-dead form all lead to similar phenotypes, including chromosome misalignment and failure to complete cytokinesis, resulting in multinucleated cells (Ruchaud et al., 2007). To gain further insights into the cellular consequences of defective Aurora-B SUMOylation, we analyzed stable HeLa cell lines expressing the mutant constructs. As reported above, proliferation of clones stably expressing GFP-Aurora-B fusion proteins was relatively normal, whereas expression of the kinase-dead and SUMO-null forms resulted in reduced viability. Accumulation of the GFP-Aurora-B fusion protein was mostly observed in G2-M cells (Fig. 4A) in agreement with its role at these cell-cycle stages. The Aurora-B mutants exhibited a slightly lower percentage of GFP-positive cells (4.3% and 3.0% in GFP-Aurora-B D205A and GFP-Aurora-B K207R, respectively, vs 5% in GFP-Aurora-B WT). Strikingly, the accumulation of these mutant proteins was not restricted to G2-M. This altered behaviour of the mutants might be explained by a higher stability of the mutant proteins or by the existence of aneuploid cells with a DNA content other than 4N.
We then depleted endogenous Aurora B by siRNA in the stable clones expressing GFP-Aurora-B fusion proteins. The mouse Aurkb cDNA, encoding Aurora B, was used to generate these constructs and they were therefore resistant to siRNA treatment directed against the endogenous human transcript (Fig. 4B). The wild-type GFP-Aurora-B construct efficiently rescued the formation of multinucleated cells after depletion of endogenous Aurora B proteins and these rescued cells progressed normally through mitosis (Fig. 4C). However, the expression of Aurora-B^D205A and Aurora-B^K207R mutants failed to rescue the defects caused by knockdown of the endogenous protein. These cultures delayed in prometaphase with unaligned chromosomes, failure to execute cytokinesis and accumulation of multinucleated cells (Fig. 4C,D). Similar results were observed after chemical inhibition of Aurora-B kinase activity with ZM447439 (ZM1; Fig. 4C,D). Quantification of the distribution of mitotic phases in these stable cell lines after depletion of endogenous Aurora B confirmed that expression of GFP-Aurora-B^D205A and GFP-Aurora-B^K207R provokes a similar arrest at prometaphase and a reduction of cells in telophase (Fig. 4E). This was accompanied by a decrease in the percentage of cells in cytokinesis. Furthermore, those cells that were undergoing cytokinesis in cultures expressing Aurora B^D205A and Aurora B^K207R were mostly aberrant and frequently displayed chromosomal bridges between the two daughter cells (Fig. 4F).

Altered chromosomal dynamics of the CPC in Aurora-B^K207R mutants

Endogenous Aurora B concentrates in the centromeric region of chromosomes during prometaphase, similarly to other CPC components such as INCENP. In the absence of endogenous Aurora B, both INCENP and exogenous wild-type GFP-Aurora-B localized properly to these centromeric structures, consistent with the functional rescue by this wild-type protein (Fig. 5A,B). Interestingly, the Aurora B^K207R mutant (as well as the kinase-dead isoform) was dispersed along the entire chromosome arms in prometaphase (PM) and metaphase (M) cells. INCENP also failed to concentrate in inner centromeres, suggesting that there are CPC localization defects upon lack of Aurora B SUMOylation. Further analysis of the distribution of Aurora B using Metamorph algorithms confirmed that Aurora B^D205A and Aurora B^K207R were dispersed along the chromosome arms (Fig. 5C-E). Quantification of the integrated optical density (OD), a measure of the opacity of an object when exposed to light, showed that the chromosomal staining of the SUMO-null Aurora B mutant is significantly (P<0.001) less opaque than Aurora-B^WT staining. This means that Aurora B^K207R does not concentrate at any chromosomal region (Fig. 5E). These defects were reduced in the kinase-dead mutant and did not reach statistical significance in this assay. We also tested whether Aurora-B kinase activity was important for proper localization of Aurora B in the centromere, by treating GFP-Aurora-B^WT cells with the ZM1 inhibitor. In agreement with previous reports (Ditchfield et al., 2003; Xu et al., 2009), chemical inhibition of Aurora B kinase activity did not perturb localization of Aurora B or INCENP to the centromere, indicating that an active kinase is not required for their centromeric localization (Fig. 5F).

Since the presence of endogenous Aurora B might interfere with the localization of exogenous Aurora-B^K207R mutants, we decided to further study these mutants in Aurora-B-knockout cells. These cells derive from Aurora-B conditional-knockout mice in which exons 2 to 6 are flanked by loxP sites [Aurkb^lox/lox] allele; G.F.-M., unpublished results]. Upon expression of the Cre recombinase (Fig. 6A), exons 2 to 6 are excised, resulting in a null allele [Aurkb^ΔΔ]. Aurkb^ΔΔ MEFs progress normally through prophase and prometaphase. However, whereas 65% of mitotic cells (n=40 of each genotype) were in metaphase, anaphase or telophase in Aurkb^lox/lox cultures, these figures were reduced to 8% in Aurkb^ΔΔ cells (most of these anaphases and telophases showed immunoreactivity against Aurora B, probably as a consequence of inefficient gene deletion; data not shown). Aurkb^ΔΔ prometaphases displayed several misaligned...
chromosomes and abnormal spindles (Fig. 6B). These defects could be rescued by infection with retroviruses expressing wild-type Aurora B, and Aurkb(ΔΔ); Aurora BWT cells displayed normal mitotic progression (about 60% mitotic cells were in metaphase, anaphase or telophase) and resulted in normal cytokinesis. In these Aurkb(ΔΔ) MEFs, the exogenous Aurora B was properly located at centromeres and migrated to the midzone during anaphase (Fig. 6B). By contrast, Aurkb(ΔΔ); Aurora BK207R cells displayed abnormal spindles and misaligned chromosomes and did not progress to anaphase (about 10% of mitotic figures in metaphase, anaphase or telophase). In these cells, the exogenous Aurora BK207R displayed an abnormal centromeric concentration and remained diffuse at chromosome arms (Fig. 6B).

Fluorescence recovery after photobleaching (FRAP) was then used to compare the relative mobility of Aurora-B isoforms at metaphase chromosomes and the mid-body. Wild-type Aurora B showed a more dynamic behavior in the chromosomes located at the metaphase plate than the other mutant isoforms (Fig. 7). Although the recovery half-life (t1/2) was 35.6±10.2 seconds for wild-type Aurora B (n=7), the kinase-dead mutant Aurora BK207R displayed a higher value (40.8±17.4 seconds; n=4), as previously reported in similar assays (Murata-Hori and Wang, 2002). A significantly higher t1/2 value (119.9±36.8 seconds; n=4) was scored in the Aurora-BK207R mutant, suggesting defective dynamics in the SUMO mutant protein. A similar recovery pattern for all the Aurora B isoforms was observed at the mid-body (t1/2=44.00±30.5 seconds).

Fig. 4. Defective mitotic progression and cytokinesis in the presence of Aurora BK207R. HeLa cells stably expressing siRNA-resistant mouse Aurora B fused to GFP were nucleofected with human AURKB siRNA oligonucleotides or a control siRNA and analyzed 36 hours after nucleofection by immunoblotting and immunofluorescence. (A) Generation and validation of HeLa stable cell lines by cytometry cell-cycle analysis. The analysis of the total cell population is shown in blue histograms, whereas the analysis of the GFP-positive population is shown in orange histograms accompanied by the percentage of these cells over the whole population. At least three different stable clones were analyzed for each GFP-Aurora-B fusion protein. Depicted histograms are from representative stable clones. (B) Western blot analysis showing efficient depletion of human endogenous Aurora B and protein levels of siRNA-resistant mouse GFP-Aurora-B proteins in HeLa stable cell lines. Tubulin was used as loading control. (C) Quantification of the percentage of interphase multinucleated cells. Stable expression of GFP-Aurora-BK207R and Aurora-BK207R induces accumulation of multinucleated cells (see picture) upon depletion of endogenous Aurora B. Around 1000 interphase cells were counted per point. (D) Quantification of the percentage of mitotic cells in prometaphase (PM) or abnormal metaphases (AM) with misaligned chromosomes (arrowheads) and multiple poles (arrows) revealing a significant arrest at these stages in cells lacking the endogenous Aurora B and stably expressing GFP-Aurora-BK207R and -Aurora-BK207R. About 50-100 mitotic cells were counted per point. Chemical inhibition of Aurora-B kinase activity with ZM447439 (ZM1) was included in C and D as a positive control. (E) Mitotic distribution of stable cell lines after depletion of endogenous Aurora B. Expression of GFP-Aurora-BK207R and -Aurora-BK207R provokes an arrest at prometaphase and a reduction in cells at telophase. P, prophase; PM, prometaphase; M, metaphase; A, anaphase; T, telophase. (F) GFP-Aurora-BK207R and -Aurora-BK207R stable cell lines display a reduced number of cells undergoing cytokinesis. In these mutant cells, the remaining cytokinesis figures are usually abnormal with chromosomal bridges (arrow). α-tubulin (α-tub) is in red, GFP-Aurora-B in green and DAPI (DNA) in blue. Scale bars: 10 μm.

The Aurora BK207R mutant displays no compromised kinase activity
The differences in localization described above suggest that the molecular defects caused by the kinase-dead and SUMO-null mutations of Aurora B are not completely identical. We therefore tested the effects of these two mutations on kinase activity. Staining with phospho-specific antibodies against CENP-A, a known Aurora-B substrate, reveals that phosphorylation of CENP-A was significantly decreased in cells expressing either Aurora BK207R or Aurora BK207R (Fig. 8A). By contrast, GFP-Aurora-BWT, which was concentrated at centromeres, efficiently phosphorylated CENP-A, resulting in positive staining for phospho-CENP-A at kinetochores flanking the GFP-Aurora-BWT signal (Fig. 8A). We next directly tested the kinase activity of V5-tagged Aurora-B proteins immunoprecipitated from transiently transfected HEK293 cells (Fig. 8B). Aurora BK1111M and Aurora BK207R failed to efficiently phosphorylate the substrate MBP in vitro, although Aurora BK1111M still displayed some kinase activity,
in agreement with the previous phenotypic analysis of these kinase-dead mutants.

Strikingly, the kinase activity of the Aurora B K207R mutant was not reduced at all and indeed it was slightly increased when compared with the activity of the wild-type protein. Similar results were obtained when a similar SUMO-defective mutant (K141R) of the highly related kinase Aurora C was used (Fig. 8C). To further corroborate whether lack of SUMOylation modulates the intrinsic kinase activity of these proteins, we performed similar kinase assays in cells transfected with Aurora B, SUMO2 and wild-type or dominant-negative forms of UBC9. Interestingly, promoting Aurora-B SUMOylation by overexpressing SUMO2 and UBC9 resulted in a slight overall decrease in Aurora-B activity, whereas preventing SUMOylation by expressing a dominant-negative form of UBC9 led to increased Aurora B kinase activity (Fig. 8D). Finally, we also tested kinase activity in human recombinant proteins produced in baculovirus. As shown in Fig. 8E, the recombinant Aurora-BK207R mutant (corresponding to mouse K207) was also active and displayed a slight increase in kinase activity. Whether this increase represents differences in the intrinsic kinase properties of the K202, K207 mutants, or is a consequence of impaired SUMOylation of the wild-type molecule in mammalian or insect cells is not clear at present. In any case, these results indicate that the functional defects in the Aurora-BK207R mutant are not a consequence of decreased kinase activity, but rather suggest that SUMOylation modulates Aurora-B function by impairing its proper removal from chromosome arms.

Fig. 5. The Aurora-B K207 residue is required for proper localization of CPC proteins at the centromere. (A) Immunofluorescence images of HeLa stable cell lines after depletion of endogenous Aurora B. Wild-type Aurora B colocalizes with INCENP at the centromeric regions. However, GFP-Aurora-BK207R and -Aurora-BK207R mutants display a disperse localization over the chromatin that also affects to INCENP in PM/M cells. Multipolar spindles are also present in these mutant cells (arrows). Scale bars: 10 μm. (B) Quantification of GFP-Aurora-B at chromosome arms from the centromere (Position 0; vertical arrow). Results are means ± s.e.m. Scale bars: 5 μm. (C) Quantification of the percentage of PM/M cells in which GFP-Aurora-B fusions and INCENP are delocalized. Delocalization of Aurora B is only observed in Aurora-BK207R and Aurora-BK207R mutants after depletion of the endogenous protein. At least 50 mitotic cells were counted per point. (D) Images pseudo-coloured with Metamorph software to visualize the distribution of GFP-Aurora-B signal in stable cell lines after depletion of endogenous Aurora B. Intensity of the signal is represented in a colour scale: (low) purple, blue, green, yellow, red (high). The contour of DNA (DAPI staining) is delineated. Scale bars: 10 μm. (E) Quantification of the integrated optical density (OD) of GFP-Aurora-B signal over the chromatin shows a significant reduction (P<0.0001) of GFP-Aurora-BK207R, but not -Aurora-BK207R, signal density. (F) Chemical inhibition of Aurora B with ZM1 does not delocalize the protein although it provokes chromosome misalignment (arrows). α-tubulin is in red in A, INCENP is in red in E, GFP-Aurora B is in green and DAPI (DNA) in blue. Scale bars: 10 μm.
Global mapping of the SUMO network by protein-protein interactions and genetic-network analysis has linked SUMOylation to many different biological processes, including chromosome segregation and the cell cycle (Makhnevych et al., 2009). In recent years, the SUMO pathway has been implicated in several aspects of mitosis, including chromosome structure, cell-cycle progression, kinetochore function and cytokinesis (Dasso, 2008; Watts, 2007).

In mammals, cells depleted of the SUMO E2-conjugating enzyme UBC9 show major deficiencies in chromosome condensation and segregation, along with severely altered nuclear morphology (Hayashi et al., 2002; Nacerddine et al., 2005), revealing the importance of this post-translational modification for mitotic progression. The CPC has been widely proposed to be regulated by SUMOylation. The yeast CPC component Bir1 (Survivin) is known to be modified by SUMO (Montpetit et al., 2006) and Sli15 (INCENP) is also a candidate for SUMO modifications in this organism (Wohlschlegel et al., 2004). Similarly, Borealin is regulated by binding to SUMO2 and SUMO3 in human cells (Klein et al., 2009).

In this work, we have identified a SUMO target site in mammalian Aurora B and analyzed the consequences of lack of SUMOylation in Aurora-B regulation and function. The SUMOylation site is highly conserved among Aurora B orthologs and in the other members of the Aurora family, Aurora A and Aurora C. Our data indicate that Aurora B can be SUMOylated in vivo by the three SUMO isoforms at Lys207 (K207). According to observations in Xenopus egg extracts and human cells, SUMO2 and SUMO3 are found at centromeres and chromatin during prometaphase and metaphase, whereas SUMO1 localizes to the mitotic spindle and the spindle mid-zone during these stages by SUMOylation. The yeast CPC component Bir1 (Survivin) is known to be modified by SUMO (Montpetit et al., 2006) and Sli15 (INCENP) is also a candidate for SUMO modifications in this organism (Wohlschlegel et al., 2004). Similarly, Borealin is regulated by binding to SUMO2 and SUMO3 in human cells (Klein et al., 2009).

In this work, we have identified a SUMO target site in mammalian Aurora B and analyzed the consequences of lack of SUMOylation in Aurora-B regulation and function. The SUMOylation site is highly conserved among Aurora B orthologs and in the other members of the Aurora family, Aurora A and Aurora C. Our data indicate that Aurora B can be SUMOylated in vivo by the three SUMO isoforms at Lys207 (K207). According to observations in Xenopus egg extracts and human cells, SUMO2 and SUMO3 are found at centromeres and chromatin during prometaphase and metaphase, whereas SUMO1 localizes to the mitotic spindle and the spindle mid-zone during these stages.
negative controls of MBP phosphorylation. Quantification of [32P]MBP signal increased. Aurora-B kinase-dead mutants K111M and D205A were included as mutations. (A) Immunofluorescence images from HeLa stable cell lines treated with siRNA against endogenous Aurora B. GFP-Aurora-BD205A and -Aurora-BK207R mutants accumulate along chromosome arms and fail to phosphorylate CENP-A. α-tubulin staining is in red (only merged in the mutant forms), phosphorylated CENP-A, if present, is in red (only merged in the wild-type forms), GFP-Aurora-B in green and DAPI (DNA) in blue. The inset represents proper dynamic localization of SUMO-null Aurora B might impair its interaction between these proteins suggests that the presence of the SUMOylation machinery. Indeed, Aurora B seems to be modified by SUMO when immunoprecipitated from cell extracts where the CPC integrity is maintained. In addition, SUMOylation of Aurora B is favoured in vitro by the presence of the IN-box domain of INCENP. Indeed, a computer simulation of the interaction between these proteins suggests that the presence of the IN-box domain of INCENP facilitates the proper energetic environment required for SUMOylation of Aurora B (Fig. 9A,B).

How might SUMO modifications modulate Aurora-B function? SUMOylation frequently alters protein surfaces and thereby positively or negatively influences interactions with other macromolecules (Geiss-Friedlander and Melchior, 2007). Thus, SUMOylation can interfere with or promote protein-protein interactions and provoke conformational changes in the modified target. The consequences of those molecular changes might influence the localization, stability or activity of a target protein in vivo. As shown in this work, SUMOylation of Aurora B seems to regulate the dynamics of Aurora-B localization at the chromosomes. SUMOylation of Aurora B seems to affect a small fraction of the Aurora B pool, although it is not clear at present whether this is a consequence of the transient nature of SUMOylation or technical problems owing to strong demodifying activity in mammalian protein extracts (Geiss-Friedlander and Melchior, 2007; Pichler, 2008). Rescue experiments performed with the Aurora-B SUMO-deficient form (Aurora BΔ207R) demonstrates that both Aurora B and INCENP fail to concentrate in inner centromeres during prometaphase or metaphase, thus suggesting that lack of Aurora-B SUMOylation affects the localization of other CPC components. Other examples of mitotic proteins whose localization at kinetochores or centromeres is regulated by SUMO include the kinesin CENP-E (Zhang et al., 2008), the CENP-H/I/K kinetochore complex (Mukhopadhyay et al., 2010) and the GTPase-activating protein RanGAP1 (Joseph et al., 2002).

It has been recently confirmed that phosphorylation of Aurora-B substrates is influenced by the relative locations of the substrate and kinase at the inner centromere (Liu et al., 2009). This mechanism offers an efficient mechanism to selectively destabilize improper microtubule-kinetochore attachments (Kelly and Funabiki, 2009). As described in the present manuscript, the SUMO-deficient form of Aurora B, despite exhibiting normal kinase activity in vitro, fails to phosphorylate CENP-A in vivo. Thus, the lack of dynamic localization of SUMO-null Aurora B might impair its interaction with its substrates, resulting in failure to phosphorylate them in vivo but not in vitro.

SUMOylation of Aurora B might also directly modulate the intrinsic kinase activity. Aurora-B D205 is crucial for kinase function and it is only two residues upstream from the SUMO-binding site (K207). Indeed, both residues are in the same structural loop (Fig. 9B). Rescue experiments with a kinase-dead mutant (Aurora BΔ205A) result in phenotypes that are similar to those obtained with the SUMO-null (Aurora BΔ207R) mutant. This led us
SUMOylation of Aurora B

Fig. 9. Modelling the Aurora-B-SUMO covalent interaction. (A) The crystal structures of human SUMO2 (Reverter and Lima, 2006) (PDB 2I03) and Xenopus Aurora B in complex with IN-box segment of INCENP (Sessa et al., 2005) (PDB 2BFY) were used to simulate the interaction between these molecules. SUMO2 might covalently bind the Aurora-B K207 residue (K218 in Xenopus crystal structure) through a finger composed of two glycine residues. SUMOylation is not predicted to affect binding of the Aurora-B partner and activator INCENP, but it might disturb the transfer of phosphate groups to its substrates. (B) Details of the ATP-binding pocket showing the localization of K111, D205 and K207 residues (K122, D216 and K218 in Xenopus, respectively) used in this study. The position of the ATP molecule was modelled after a superposition with the Aurora-A-TPX2 structure (PDB 1OL5). (C) A model for the role of SUMOylation of Aurora B in CPC function. SUMOylation of Aurora B might result in decreased kinase activity, probably as a consequence of interference of the SUMO residue with kinase function. In addition, the presence of the SUMO residue might trigger an unknown pathway that favours the removal of Aurora B and the CPC from chromatin. MT, microtubule.

In summary, our data suggest that Aurora-B function is modulated by SUMOylation at K207. This modification is likely to interfere with Aurora-B kinase activity and it might participate in the extraction of the CPC from chromatin during prometaphase and the metaphase-to-anaphase transition. The effects of SUMOylation on the dynamic localization of Aurora B might be linked to ubiquitylation by the Cul3-Klhl9/Klhl13 ligase, because prevention of either SUMOylation or ubiquitylation by this complex results in a similar phenotype where the CPC is delocalized on chromosomes. The regulation of Aurora B by SUMOylation might also have relevant implications, not only in preventing genomic instability, but also in tumorigenesis and cancer therapy (Girdler et al., 2006; Keen and Taylor, 2004; Mo and Moschos, 2005; Perez de Castro et al., 2007; Perez de Castro et al., 2008).

Materials and Methods

Sequence analysis and gene constructs

For protein-domain analysis, we first used the ELM (Eukaryotic Linear Motif, http://elm.eu.org) algorithm. To further confirm the presence of SUMO motifs we used the specific SUMO prediction software SUMOplot Analysis Program (http://www.abgent.com/tools/SUMOplot). Sequence alignments were obtained with the Clustal software (http://www.ebi.ac.uk/Tools/clustalw2/index.html). Mouse Aurb cDNA was amplified by PCR from the plasmid mAa0155 (Mammalian Gene Collection), cloned into pENTR-D-TOPO vector using TOPO technology (Invitrogen) and transferred to a destiny vector coexpressing GFP or V5 tag by a LR recombination reaction of the Gateway system (Invitrogen). Aurora-B mutants (Aurora BK111M, Aurora B^K111M^ and Aurora B^K207R,^ were prepared using the Quik-Change site-directed mutagenesis kit (Stratagene) and were verified by DNA sequencing. Plasmids expressing histidine- or HA-tagged SUMO1, SUMO2 and SUMO3 as well as wild-
type UBC9 or the UBC9 C93S mutant were kindly provided by Ron Hay (Wellcome Trust Centre for Gene Regulation and Expression, University of Dundee, UK).

**Cell culture, transfection and cell-cycle analysis**

HEK293, U2OS and HeLa human cells were maintained in DMEM medium supplemented with 10% foetal bovine serum and antibiotics and were grown at 37°C in a humidified 5% CO2 atmosphere. The generation of conditional alleles at the mouse Aurkl locus will be described elsewhere. Mouse embryo fibroblasts were obtained from E14.5 Aurkllox/lox embryos and cultured using routine protocols (Garcia-Higuera et al., 2008). Human Aurora B was silenced using validated siRNA oligos (Becton Dickinson). Data were processed using FACSDiva software (Becton Dickinson). For immunofluorescence experiments, siRNA oligos were nucleofected in HeLa cells using Amaxa kit and the conditions provided by Amaxa 113 protocol. Cell-cycle distribution was determined by flow cytometry after DNA staining with propidium iodide (Sigma) and analyzed on a FACSCanto flow cytometer (Becton Dickinson). For silencing experiments, siRNA oligos were nucleofected in HeLa cells using Effectene transfection reagent (Qiagen) according to the manufacturer’s instructions. For silencing experiments, siRNA oligos were nucleofected in HeLa cells using Amaxa kit and the conditions provided by Amaxa 113 protocol.

**Protein extraction and analysis**

Total protein lysates extracted from HEK293 cells transiently transfected with V5-tagged Aurora-B vectors were prepared with protein G-agarose bead suspension for 1 hour (Amersham). Supernatants were first incubated for 2 hours at 4°C on a rotating wheel with mouse anti-V5 (Invitrogen) and later with 50 µl of the blocked beads. Immunoprecipitation for an additional hour. Immunoprecipitates were then washed three times in RIPA buffer and, in case of the kinase assay, one extra wash was performed with RIPA plus 0.5 M NaCl to remove possible bound unspecific kinases. One fifth of the immunoprecipitates bound to the beads were used for V5 detection by western blot. For the kinase assay, four filths of the beads from the previous immunoprecipitations or recombinant proteins (Millipore) were washed in kinase assay buffer [10 mM HEPES-NaOH (pH 7.4), 150 mM NaCl, 10 mM MgCl2, and 1 mM EGTA] supplemented with 0.5 mM DTT and phosphatase inhibitor cocktail (Calbiochem) and later incubated in 25 µl of 2× kinase buffer supplemented with 2 mM ATP, 2.5 µCi [γ-32P]ATP and 3 µg MBP (Sigma) or histone H3 (New England Biolabs) as an Aurora substrate. The reactions were incubated for 30 minutes at 30°C, stopped by addition of 5 µl of 5× Laemmli sample buffer, separated by 12.5 % SDS-PAGE and analyzed by autoradiography.

We thank Susana Temiño for technical assistance, Diego Megias for support in image processing and Ron Hay and Manuel Valdivia for reagents. G.F.M. was supported by a fellowship from the Comunidad de Madrid. I.P.C. was supported by a Ramón y Cajal contract. Work in the W.C.E. lab is funded by The Wellcome Trust. G.F.M. is funded by grants CSD2006-00203, and BFU2008-01344 from the Spanish Ministry of Science and Innovation (MICINN). The Cell Division and Cancer Group of the CNIO is funded by grants from the Association for International Cancer Research (AICR 08-0188), Fundación Mutua Madrileña Automovilista, Fundación Ramón Areces, MICINN (SAF2007-64571 to I.P.C.; and SAF2006-05186 and SAF2009-07973 to M.M.), the OncoCycle Programme (S-BIO-0283-2006) from the Comunidad de Madrid, and the OncoBIO Consolider-Ingenio 2010 Programme (CSD2007-00017) from the MICINN, Madrid. Deposited in PMC for release after 6 months.

**References**


